DOD, Spinal Cord Injury Research Program, Investigator-Initiated Research Award | W81XWH 22 SCIRP IIRA

Opportunity Information: Apply for W81XWH 22 SCIRP IIRA

The Department of Defense Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA), funding opportunity number W81XWH-22-SCIRP-IIRA, is a discretionary research funding mechanism offered through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to support investigator-driven studies that can make a meaningful and measurable contribution to spinal cord injury (SCI) research, improve patient care, and/or enhance quality of life for people living with SCI. The award can be made as either a grant or a cooperative agreement, and it sits within the Science and Technology and other Research and Development category (CFDA 12.420). Eligibility is broadly open (unrestricted), meaning a wide range of organizations and entity types may apply, subject to any additional eligibility clarifications contained in the full announcement.

A central requirement of the IIRA is impact. Applicants are expected to clearly explain why their work matters now and how it could change the field over time, not only in terms of scientific advancement but also in practical benefit to the SCI community. Proposals must align with one or more of the SCIRP Focus Areas for FY22, so the project needs to be framed within the program priorities rather than being an entirely open-topic SCI proposal. Reviewers are looking for a convincing narrative that connects the proposed aims to near-term outputs (such as improved understanding of mechanisms, validation of an intervention in a relevant model, or actionable clinical insights) and longer-term outcomes that could realistically improve function, secondary complications, independence, and daily life for individuals with SCI.

Another major emphasis is relevance to military health. The program specifically wants research that is pertinent to spinal cord-injured Service Members and Veterans, and it also recognizes the broader care ecosystem by highlighting the importance of family members and care partners. While civilian impact is not excluded, the proposal should make an explicit case for why the problem and the proposed solution matter to the military and Veteran population. The announcement also encourages collaboration with military and Department of Veterans Affairs (VA) researchers and clinicians, signaling that partnerships that facilitate access to military-relevant populations, clinical expertise, or real-world care settings may strengthen an application.

The opportunity also requires preliminary support for the proposed work. Rather than funding purely speculative ideas, the IIRA expects applicants to include preliminary and/or published data that are directly relevant to SCIRP goals and that substantiate feasibility and rationale. The solicitation makes clear that these early observations can come from multiple sources, including laboratory findings, population-level studies, clinician experience with patients, or even anecdotal observations, as long as they credibly motivate the research question and support the proposed approach. In practical terms, the application should show evidence that the central hypothesis is grounded, the methods are workable, and the team is positioned to execute the project successfully.

In terms of scope, the IIRA supports a wide span of research stages, from basic science through translational work, but it discourages projects focused exclusively on target identification. That means applicants can pursue mechanistic studies, proof-of-concept testing, development and refinement of interventions, or translational studies that bridge toward clinical relevance, but they should avoid proposals that stop at simply naming or nominating a molecular target without a broader plan to evaluate utility, mechanism, or translational pathway. The permitted research approaches include preclinical studies in animal models (with some limitations noted in the full program guidance), studies involving human subjects, work using human anatomical substances, and ancillary studies tied to an existing clinical trial. However, the award explicitly does not allow clinical trials under this funding opportunity, so applicants must ensure their design does not meet the definition of a clinical trial even if it involves human participants.

For projects that use animals, the program places special attention on model justification. Applicants must clearly explain why the selected animal model is appropriate and how it relates to human SCI, which typically includes details on injury type, level, severity, timing, and outcome measures, as well as why that model is suitable for the specific question being tested. The intent is to ensure that preclinical work is not only scientifically sound but also meaningfully translatable, with outcomes that can inform human biology, clinical decision-making, or future intervention development.

Administratively, the opportunity was posted March 28, 2022, with an original closing date of September 2, 2022, and the program anticipated making around seven awards. The listing shows an award ceiling of 0, which generally indicates that the maximum award amount is not stated in that particular summary field and would typically be defined in the full announcement or related budget guidance. Overall, the IIRA is best understood as a competitive, impact-focused mechanism for well-supported, mission-relevant SCI research that is grounded in preliminary evidence, aligned with SCIRP priority focus areas, and positioned to advance outcomes that matter to Service Members, Veterans, and the broader SCI community, while staying clearly outside the boundaries of conducting a clinical trial.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD, Spinal Cord Injury Research Program, Investigator-Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 28, 2022.
• Applicants must submit their applications by Sep 02, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 7 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 SCIRP IIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: